HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon restructuring

This article was originally published in The Rose Sheet

Executive Summary

Beauty giant announces new target of $900 mil. for its ongoing restructuring initiative. In addition to continuing efforts at product line simplification, Avon will launch a new program in the second half of 2009 to increase efficiency across its global supply chain through outsourcing and consolidating local business support functions into regional ones, it says Feb. 19. Firm is optimistic that the $300-$400 mil. project will achieve annualized savings of $200 mil. when fully implemented. "Our original restructuring program began in 2005, and over the last three years we have been dramatically transforming our cost structure and exceeding our original savings estimates as we fix the fundamentals of our business," Vice Chairman and Chief Finance and Strategy Officer Charles Cramb said. Firm's original restructuring program will deliver savings of $430 mil., by 2011-2012, Avon predicts, and an additional $200 mil. and $250 mil. in savings are expected by 2010, respectively, from product line simplification and strategic sourcing measures taken separately. In 2008, Avon reported that savings from its various restructuring programs were beginning to accrue (1"The Rose Sheet" Aug. 4, 2008, p. 9)

You may also be interested in...



Avon Restructuring Program Paying Off In Q2

Avon's second-quarter sales and earnings performance signals that the company is realizing benefits of its three-year-old restructuring program while effectively offsetting high commodity costs, the firm indicated during a July 30 earnings call

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel